NEW YORK, NY / ACCESS Newswire / March 20, 2025 / If you suffered a loss on your Crocs, Inc. (NASDAQ:CROX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/crocs-inc-lawsuit-submission-form?prid=137368&wire=1 or contact Joseph E. Levi, Esq.

NEW YORK, NY / ACCESS Newswire / March 20, 2025 / If you suffered a loss on your Fluence Energy, Inc. (NASDAQ:FLNC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/fluence-energy-lawsuit-submission-form?prid=137365&wire=1 or contact Joseph E. Levi, Esq.

NEW YORK, NY / ACCESS Newswire / March 20, 2025 / If you suffered a loss on your Ready Capital Corporation (NYSE:RC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/ready-capital-corporation-lawsuit-submission-form?prid=137369&wire=1 or contact Joseph E. Levi, Esq.

NEW YORK, NY / ACCESS Newswire / March 20, 2025 / If you suffered a loss on your TransMedics Group, Inc. (NASDAQ:TMDX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/transmedics-group-inc-lawsuit-submission-form-2?prid=137370&wire=1 or contact Joseph E. Levi, Esq.

It's been nearly five years since Moderna (MRNA -1.60%) emerged as a biotech industry disruptor, with its COVID-19 vaccine playing a landmark role in tackling the global pandemic in late 2020. Despite its generating record sales and profits through 2022, early projections of sustained demand for coronavirus vaccinations failed to materialize, leading to a sharp drop in the business.

President Donald Trump indicated he is open to extending Chevron's license to produce oil in Venezuela during a meeting with oil executives Wednesday, according to The Wall Street Journal. The Trump administration had given Chevron until April 3 to wind down its operations.

Robinhood's earnings are accelerating, with a diversified revenue stream and strong operational performance, making it a strong buy despite the recent market selloff. The company's Q4 performance dramatically beat expectations, driven by explosive growth in crypto and options trading, signaling underestimated EPS estimates for 2025. Robinhood's high-margin business model and expanding market share support a compelling long-term bull case, with the potential for significant EPS growth and valuation upside.

Ernest Hoffman is a Crypto and Market Reporter for Kitco News. He has over 15 years of experience as a writer, editor, broadcaster and producer for media, educational and cultural organizations.

SCHG has delivered impressive performance, achieving an 828% total return since its inception in 2009, significantly outpacing the broader market's 578% return. Growth investing isn't about picking winners like Amazon or NVIDIA, it's about leveraging a concentrated strategy to deliver outsized returns. Value investing has historically outpaced growth over the last century. With shifting market conditions in 2025, funds like SCHD or stocks like NVIDIA could blend growth and fundamentals for an edge.

Following continuous trade tensions between the European Union and the United States, the European Commission moved forward with the enforcement of its digital antitrust rules on Alphabet's Google and Apple.

In this podcast, Motley Fool analyst David Meier and host Dylan Lewis discuss:

PDD Holdings Inc. Sponsored ADR (PDD) came out with quarterly earnings of $2.76 per share, beating the Zacks Consensus Estimate of $2.56 per share. This compares to earnings of $2.40 per share a year ago.

2024 Full-year revenues increased by 5.2% year over year, reaching a record-breaking $2.76 billion, while net income grew by 24.5% to a record-breaking $79.7 million 2024 Full-year revenues increased by 5.2% year over year, reaching a record-breaking $2.76 billion, while net income grew by 24.5% to a record-breaking $79.7 million

Some investors downplay the link between politics and investing, and sometimes Capitol Hill events have little impact. But if it were all irrelevant, why would so many members of Congress trade stocks based on the information they receive?

Many issues are creating uncertainty for investors, but tariffs are one of the main ones in 2025. In mid-March, the Trump administration announced 25% tariffs on all steel and aluminum products entering the United States.

Regina, Saskatchewan--(Newsfile Corp. - March 20, 2025) - Above Food Ingredients Inc. (NASDAQ: ABVE) ("the Company") announces today that as part of its strategic pivot towards the Agri-Tech and Fin-Tech sectors it has consented to the application filed by the Royal Bank of Canada to wind up the Company's Purely Canada Food Corp. subsidiaries ("PCFC"), which was filed on March 3, 2025 at the Court of King's Bench in Saskatchewan. Consequently, the Court on March 19, 2025, ordered that PCFC be placed into receivership.

If you're one of the over 4 Million Americans set to retire this year, you may want to pay attention.

COLORADO SPRINGS, Colo.--(BUSINESS WIRE)--Venu Holding Corporation ("VENU" or "The Company") (NYSE American: VENU), a developer, owner, and operator of upscale live music venues and premium hospitality destinations, announced today that it intends to release its 2024 annual results for its 2024 fiscal year and will host a conference call at 4:30 p.m., Eastern Time, on Monday, March 31st, 2025, to discuss The Company's 2024 year-end financial results and business progress. Conference Call Detail.

Darden Restaurants (DRI) reported fiscal 2025 third-quarter adjusted profits in line with analysts' estimates but same-restaurant sales came up well short.

Across two trials, 9 of 10 frontline AML patients achieved remission when treated with mipletamig in combination with the standard of care Triplet Combination with mipletamig continues to outperform doublet combination benchmark No Cytokine Release Syndrome (CRS) has been observed in the RAINIER trial to date Cohort 2 enrollment nears completion SEATTLE, WA / ACCESS Newswire / March 20, 2025 / Aptevo Therapeutics ("Aptevo") (NASDAQ:APVO), a clinical-stage biotechnology company developing novel bispecific immuno-oncology therapeutics based on its proprietary ADAPTIR® and ADAPTIR-FLEX® platform technologies, today announced two additional frontline AML patients have achieved remission* within 30 days of treatment in the …